John Strickler

33PUBLICATIONS
168CO-AUTHORS
Cancer geneticsChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 27, 2026
Access to Guideline-Concordant Oncology Genomic Testing: A Qualitative Study of Black Cancer Patients and Oncology Providers.

|Jul 23, 2026
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Apr 03, 2026
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Daniel Walden, Felipe Batalini, Cody Eslinger

|Mar 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler, Judith Raimbourg, Jonathan E Cohen

|Jan 21, 2026
Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites States.

Jenny O'Brien, Ryne C Ramaker, Ashley Moyer

Pageof 6

Frequent Collaborators

5 joint publications

Tanios S Bekaii-Saab

3 joint publications

David S Hong

3 joint publications

Apurvasena Parikh

3 joint publications

Tomi F Akinyemiju